MRNA:NASDAQModerna, Inc. Analysis
Data as of 2026-08-26 - not real-time
$147.85
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Moderna, Inc. is priced at $147.85 and its moving averages line up in bullish order, the shorter sitting above the longer. The last 30 days have gained 116.5%. RSI sits at 67.8, which reads as approaching overbought, and MACD momentum is bullish. Watch $52.66 as support and $176.66 as the nearer resistance level.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 35.3% below where the shares trade now. Revenue is growing at 2.1% on a -141.4% profit margin.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 317.2%, a beta of 1.91 and a maximum drawdown of 34.2%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
All three time horizons resolve to hold, carrying 3/10 conviction.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 35.3% below where the shares trade now. Revenue is growing at 2.1% on a -141.4% profit margin.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 317.2%, a beta of 1.91 and a maximum drawdown of 34.2%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
All three time horizons resolve to hold, carrying 3/10 conviction.
Top Market Events
A number of stocks fell in the afternoon session after shares across biotech and big pharma cooled further as traders...A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA...David Moadel Tue, August 25, 2026 at 2:24 PM UTC 0 sanjeri / E+ via Getty Images Quick Read - Moderna surged 11% while...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 50.60
- MACD momentum is positive
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 50.60
- Analyst targets imply -35.3% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- Negative profit margin of -141.4%
- Analyst targets imply -35.3% versus the current price
- Negative return on equity of -39.0%
Key Metrics & Analysis
Financial Health
Revenue Growth2.10%
Profit Margin-141.43%
P/E Ratio-32.1
ROE-39.00%
ROA-13.26%
Debt/Equity19.04
P/B Ratio8.7
Op. Cash Flow$-1073000000
Free Cash Flow$299.2M
Industry P/E31.0
Technical Analysis
TrendBullish
RSI67.8
Support$52.66
Resistance$176.66
MA 20$86.55
MA 50$73.48
MA 200$50.60
MACDBullish
VolumeIncreasing
Fear & Greed Index93.89
Valuation
Fair Value$20.14
Target Price$95.67
Upside/Downside-35.29%
GradeOvervalued
TypeBlend
Risk Assessment
Beta1.91
Volatility317.22%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.